55379-99-2

Upstream product

• 7400-08-0 para-coumaric acid 
• 106-95-6 allyl bromide 
• 3943-97-3 methyl p-hydroxycinnamate 
• 141-82-2 malonic acid 
• 40663-68-1 4-(2-propenyloxy)benzaldehyde 
• 7400-08-0 p-Coumaric Acid 

Downstream Products

• 219502-13-3 (E)-3-(4-Allyloxy-phenyl)-acryloyl chloride 
• 928214-90-8 2'-(4-allyloxycinnamoyloxy)-4',6'-dimethoxyacetophenone 
• 928214-98-6 4'-allyloxy-5,7-dimethoxy-2-styrylchromone 

Relevant academic research and scientific papers

TRUNCATED ITRACONAZOLE ANALOGUES AND METHODS OF USE THEREOF

Disclosed herein are analogues of itraconazole that are potent hedgehog signaling pathway inhibitors. The compounds are expected to be useful in the treatment of cell proliferation disorders such as cancer, particularly cancers that are dependent upon the hedgehog signaling pathway such as basal cell carcinoma and medulloblastoma.

Truncated Itraconazole Analogues Exhibiting Potent Anti-Hedgehog Activity and Improved Drug-like Properties

We conducted a structure-activity relationship study to explore simplified analogues of the itraconazole (ITZ) scaffold for their ability to inhibit the hedgehog (Hh) signaling pathway. These analogues were based on exploring the effects of chemical modifications to the linker and triazolone/side chain region of ITZ. Analogue 11 was identified as the most potent compound in our first generation, with an IC50 value of 81 nM in a murine Hh-dependent basal cell carcinoma. Metabolic identification studies led us to identify truncated piperazine (26) as the major metabolite in human liver microsomes (HLMs) and an improved Hh pathway inhibitor (IC50 = 22 nM). This work verifies that continued truncation of the ITZ scaffold is a practical method to maintain potent anti-Hh activity while also reducing the molecular weight for the ITZ scaffold and achieving improved pharmacokinetic properties.

Synthesis, cytotoxicity and molecular modelling studies of new phenylcinnamide derivatives as potent inhibitors of cholinesterases

The present study reports the synthesis of cinnamide derivatives and their biological activity as inhibitors of both cholinesterases and anticancer agents. Controlled inhibition of brain acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) may slow neurodegeneration in Alzheimer's diseases (AD). The anticholinesterase activity of phenylcinnamide derivatives was determined against Electric Eel acetylcholinesterase (EeAChE) and horse serum butyrylcholinesterase (hBChE) and some of the compounds appeared as moderately potent inhibitors of EeAChE and hBChE. The compound 3-(2-(Benzyloxy)phenyl)-N- (3,4,5-trimethoxyphenyl)acrylamide (3i) showed maximum activity against EeAChE with an IC50 0.29 ± 0.21 μM whereas 3-(2-chloro-6- nitrophenyl)-N-(3,4,5-trimethoxyphenyl)acrylamide (3k) was proved to be the most potent inhibitor of hBChE having IC50 1.18 ± 1.31 μM. To better understand the enzyme-inhibitor interaction of the most active compounds toward cholinesterases, molecular modelling studies were carried out on high-resolution crystallographic structures. The anticancer effects of synthesized compounds were also evaluated against cancer cell line (lung carcinoma). The compounds may be useful leads for the design of a new class of anticancer drugs for the treatment of cancer and cholinesterase inhibitors for Alzheimer's disease (AD).

Synthesis of n′-allyl-2-styrylchromones by a Baker Venkataraman transformation

n′-allyl-2-styrylchromones have been prepared by the Baker-Venkataraman method, by two different synthetic routes, both of them involving a Claisen rearrangement. The two synthetic routes were compared in terms of yields and practical execution. All compo

Studies of hypolipidemic agents. 1. Synthesis and hypolipidemic activities of alkoxycinnamic acid derivatives

More than 110 derivatives of alkoxycinnamic acids were synthesized and their hypolipidemic activities were evaluated in a screening system with rats. Cinnamic acids, α-methylcinnamic acids, and their various esters with a higher p-alkoxy substituent were